Overview

The Therapeutic Goods (Manufacturing Principles) Determination No 1 of 2000, made by Terry Slater, a delegate of the Minister for Health and Aged Care, amends the Therapeutic Goods Manufacturing Principles No.1 of 1999 to ensure the manufacture of blood and blood components for human use adheres to specific guidelines and quality assurance systems. This legislative instrument addresses the need for stringent manufacturing principles to ensure the safety and efficacy of therapeutic goods, particularly blood and blood components, by mandating compliance with the Australian Code of GMP for Human Blood and Tissues. The policy objective is to maintain high standards in the manufacturing of therapeutic goods, thereby safeguarding public health. This Determination came into effect on the date it was gazetted and requires manufacturers to lodge a Technical Master File with their application for a licence under the Therapeutic Goods Act 1989.

Scope and Application

The Therapeutic Goods (Manufacturing Principles) Determination No 1 of 2000 applies to entities and individuals involved in the manufacture of blood and blood components intended for use in humans, such as blood banks, manufacturing facilities, and medical laboratories. This legislative instrument pertains to the manufacturing principles and practices for therapeutic goods within the Commonwealth of Australia, specifically those that fall under the jurisdiction of the Therapeutic Goods Act 1989. The Determination mandates compliance with The Australian Code of Good Manufacturing Practice for Human Blood and Tissues and requires the lodgement of Technical Master Files as part of the licensing application process for blood and blood components. It specifies the conditions under which these products must be manufactured to ensure their safety, quality, and efficacy, and thereby seeks to protect public health by establishing and enforcing stringent manufacturing standards. The Determination also removes outdated definitions and clauses from the 1999 Manufacturing Principles, updating the regulatory framework to reflect current best practices and technological advancements in the field of blood and blood component manufacturing.

Key Provisions

The Therapeutic Goods (Manufacturing Principles) Determination No 1 of 2000 primarily amends the Therapeutic Goods Manufacturing Principles No. 1 of 1999 by deleting certain definitions and subclauses, and introduces new principles to be observed in the manufacture of blood and blood components for human use. The changes are detailed under section (a) of the Determination, which removes the definitions of “Human Tissues Code of GMP” and “Blood and Blood Components Code of GMP” from the original document and deletes subclauses 5(1) and (3). Section (b) then outlines the new principles for the manufacture of blood and blood components, which must comply with The Australian Code of Good Manufacturing Practice for Human Blood and Tissues and relevant Technical Master Files. Under the new provisions, manufacturers of blood, blood components, and plasma must adhere to specific requirements. Section 1 mandates that a Technical Master File be lodged with an application for a licence under Part 4 of the Therapeutic Goods Act 1989. Section 2 stipulates that blood and blood components must be manufactured in compliance with the Australian Code of GMP for Human Blood and Tissues and in a manner consistent with the relevant Technical Master Files. Additionally, human tissues must also be manufactured in compliance with the Australian Code of GMP for Human Blood and Tissues. Failure to comply with the obligations and requirements outlined in the Determination can lead to legal consequences. While the Determination itself does not explicitly state specific offences, penalties, or maximum penalties, non-compliance may result in enforcement actions under the Therapeutic Goods Act 1989. This could include fines, revocation of licences, or other civil or criminal penalties as prescribed by the Act. It is essential for manufacturers to adhere to the established principles and requirements to avoid any adverse legal repercussions.